A Study To Compare The Serum Cytokines Level With The Immuno-Histochemistry (Ihc) In Breast Cancer Patients
Keywords:
Inflammatory Cytokines, Breast Malignancy, Immuno-Histochemistry (IHCAbstract
Introduction: Breast cancer is the most frequently diagnosed cancer and is the foremost cause of death among women worldwide. The cytokine concentrations in the blood can be used as a predictor of prognosis and immunity in the case of cancer. This study was planned to compare the serum cytokines level with the Immuno-histochemistry (IHC) among patients with clinically suspected breast malignancy.
Material & Methods: This was a prospective study. It will include all breast cancer patients in NIMS University Rajasthan Jaipur. All study subjects undergone a detailed clinical assessment, including medical history and family history of cancer, physical examination of the breast and axilla, radiological imaging and biopsy for histopathological confirmation. Quantification of cytokines was performed using enzyme-linked immunosorbent assay (ELISA) kits specific to each cytokine.
Results: The serum levels of pro-inflammatory cytokines IL-2, IL-6, IL-12, IFN-γ, IFN-α, and IFN-β were significantly elevated in the malignant group compared to the benign group (p < 0.001). Similarly, the anti-inflammatory cytokines IL-4, IL-10, and IL-11 also showed a significant increase in confirmed malignant cases (p < 0.01). Elevated levels of IL-6, IL-10, and IL-12 were significantly associated with HER2-positive tumors (p = 0.001). Triple-negative breast cancer (TNBC) cases (n = 11) demonstrated the highest levels of IFN-γ and IL-6, suggesting a more inflammatory microenvironment.
Conclusion: The altered serum cytokine profiles observed in this study support the hypothesis that systemic inflammation is intricately linked with breast cancer development. Both pro- and anti-inflammatory cytokines may serve as valuable adjuncts in early detection, prognosis, and therapeutic monitoring of breast malignancy.
Downloads
References
A.Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics, CA Cancer J. Clin. 61 (2011) 69–90.
Roitt, I., editor. Immunology. C.V. Mosby; New York: 2006.
Cooke, A.; Owen, M.; Trowsdale, J.; Champion, B. Advanced immunology. Mosby; London: 1996. chapter 10.1–10.13
Bordbar E, Malekzadeh M, Ardekani M, Doroudchi M, Ghaderi A. Serum Levels of G-CSF and IL-7 in Iranian Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention. 2012;13(10):5307-5312.
R. Etzioni, N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. Reid, J. Radich, G. Anderson, L. Hartwell, The case for early detection, Nat. Rev. Cancer 3 (2003) 243–252.
R.J. Hooley, L. Andrejeva, L.M. Scoutt, Breast cancer screening and problem solving using mammography, ultrasound, and magnetic resonance imaging, Ultrasound Q 27 (2011) 23–47.
Suri C, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 182: 468–471.
Teicher BA, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 1–6.
Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL- 6), interleukin-8 (IL-8)
Kaur R, Vasudeva K, Singla H, Benipal R, Khetarpal P, Munshi A. Analysis of pro‐ and anti‐inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer. Journal of Cellular Physiology. 2018;233(12):9716-9723.
Bordbar E, Malekzadeh M, Ardekani M, Doroudchi M, Ghaderi A. Serum Levels of G-CSF and IL-7 in Iranian Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention. 2012;13(10):5307-5312.
Wang H, Yang X. Association between serum cytokines and progression of breast cancer in Chinese population. Medicine. 2017;96(49):e8840.
Lyon D, McCain N, Walter J, Schubert C. Cytokine Comparisons Between Women With Breast Cancer and Women With a Negative Breast Biopsy. Nursing Research. 2008;57(1):51-58.
Li L, Chen L, Zhang W, Liao Y, Chen J, Shi Y et al. Serum cytokine profile in patients with breast cancer. Cytokine. 2017;89:173-178
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
